Rhumbline Advisers Acquires 88,328 Shares of Gilead Sciences, Inc. $GILD

Rhumbline Advisers lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,343,468 shares of the biopharmaceutical company’s stock after purchasing an additional 88,328 shares during the period. Rhumbline Advisers’ holdings in Gilead Sciences were worth $259,820,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. GoalVest Advisory LLC lifted its position in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the last quarter. Activest Wealth Management increased its holdings in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $27,000. Putney Financial Group LLC lifted its holdings in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the last quarter. Finally, Colonial Trust Advisors lifted its holdings in Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Wolfe Research lifted their price target on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research report on Friday, October 31st. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Gilead Sciences in a research report on Monday, November 3rd. Finally, Wall Street Zen raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $130.45.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.23, for a total value of $313,075.00. Following the completion of the transaction, the chief financial officer directly owned 154,555 shares of the company’s stock, valued at $19,354,922.65. This trade represents a 1.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the sale, the insider owned 107,193 shares in the company, valued at $13,491,310.98. This represents a 20.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 125,146 shares of company stock valued at $15,148,441. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 1.3%

Shares of GILD opened at $126.64 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a 50-day simple moving average of $118.48 and a 200-day simple moving average of $113.54. Gilead Sciences, Inc. has a 52 week low of $88.57 and a 52 week high of $128.70. The firm has a market capitalization of $157.12 billion, a P/E ratio of 25.23, a P/E/G ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same period last year, the business earned $2.02 earnings per share. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is currently 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.